

1c685 U.S. PTO
07/19/00

Patent
Attorney's Docket No. 016800-390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING CONTINUATION/DIVISIONAL
APPLICATION UNDER 37 C.F.R. § 1.53(b)

3c598 U.S. PTO
09/619584
07/19/00

Box PATENT APPLICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a request for filing a ☐ continuation ☒ divisional application under 37 C.F.R.
§ 1.53(b) of pending Application No. 08/952,804 filed on January 26, 1998, for BICYCLIC
AROMATIC COMPOUNDS, by the following named inventor(s):

- (a) Full Name Jean-Michel BERNARDON
- (b) Full Name _____
- (c) Full Name _____

- ☒ The entire disclosure of the prior application from which a copy of the oath or declaration is
supplied herewith is considered as being part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.
- ☐ This application is being filed by less than all the inventors named in the prior application.
In accordance with 37 C.F.R. 1.63(d)(2), the Commissioner is requested to delete the
name(s) of the following person or persons who are not inventors of the invention being
claimed in this application.

- (a) Full Name _____
- (b) Full Name _____
- (c) Full Name _____

- ☐ This application is being filed by more than all the inventors named in the prior application.
In accordance with 37 C.F.R. 1.63(d)(2), the Commissioner is requested to add the name(s)
of the following person or persons who are inventors of the invention being claimed in this
application.



21839

(2/00)

- (a) Full Name _____
- (b) Full Name _____
- (c) Full Name _____

1. ☒ Enclosed is a copy of the prior Application No. 08/952,804 as originally filed on January 26, 1998, including copies of the specification, claims, drawings and the executed oath or declaration as filed.
2. ☐ Enclosed is a revised prior application and a copy of the prior executed oath or declaration as filed. No new matter has been added to the revised application.
3. ☐ _____ statement(s) claiming small entity status ☐ are enclosed ☐ were filed in prior Application No. __, filed on __.
4. ☒ The filing fee is calculated below ☒ and in accordance with the enclosed preliminary amendment:

CLAIMS					
	NO. OF CLAIMS		EXTRA CLAIMS	RATE	FEE
Basic Application Fee					\$690.00 (101)
Total Claims	21	MINUS 20 =	1	x \$18.00 (103) =	\$18.00
Independent Claims	1	MINUS 3 =	0	x \$78.00 (102) =	0.00
If multiple dependent claims are presented, add \$260.00 (104)					
Total Application Fee					\$708.00
If small entity status is claimed, subtract 50% of Total Application Fee					
Add Assignment Recording Fee of if Assignment document is enclosed					
TOTAL APPLICATION FEE DUE					\$708.00

5. ☐ Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.
6. ☒ A check in the amount of \$ 708.00 is enclosed for the fee due.


- 006720-48567950
7. ☒ The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.
8. ☒ Cancel in this application original claims 2-11 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
9. ☒ Amend the specification by inserting before the first line the sentence: --This application is a ☐ continuation, ☒ divisional, of Application No. 08/952,804, filed January 26, 1998.--
10. ☐ Transfer the drawings from the pending prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate of this paper is enclosed for filing in the prior application file. (May only be used if signed by person authorized under 37 C.F.R. § 1.138 and before payment of issue fee.)
11. ☒ New drawings are enclosed.
12. ☒ Priority of Application No. 96/03235 filed on March 14, 1996 in France (country) is claimed under 35 U.S.C. § 119.
- ☒ The certified copy of the priority application
- ☐ is enclosed
- ☒ was received by the International Bureau on April 10, 1997 in connection with International Application No. PCT/FR97/00391, of which prior Application No. 08/952,804 is the U.S. national phase.
- ☐ has not yet been filed.
13. ☒ A preliminary amendment is enclosed.
14. ☒ An Information Disclosure Citation (PTO Form 1449) filed in prior Application No. 08/952,804 is enclosed.
15. ☐ A General Authorization for Payment of Fees and Petitions for Extensions of Time is enclosed.
16. ☐ Also enclosed __.
17. ☒ The power of attorney in the prior application is to Norman H. Stepno, Reg. No. 22,716.
- a. ☒ The power appears in the original papers in the prior application.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ Recognize as Associate Attorney Robin L. Teskin, Reg. No. 35,030.

- d. ☒ Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)

Norman H. Stepno
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

Date: July 19, 2000
Date

By:


Norman H. Stepno
Registration No. 22,716

ADDRESS OF
SIGNATOR:

BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

☐ inventor(s)
☐ assignee of complete interest
☒ attorney or agent of record
☐ filed under 37 C.F.R. § 1.34(a)

006720-48567960

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Jean-Michel BERNARDON) Group Art Unit: Unassigned
)
Application No.: Unassigned) Examiner: Unassigned
(Divisional of Appln. No. 08/952,804))
)
Filed: July 19, 2000)
)
For: BICYCLIC AROMATIC)
COMPOUNDS)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please first amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, line 2, insert "BRIEF SUMMARY OF THE INVENTION";

Page 1, after line 25, insert the following text:

--BRIEF DESCRIPTION OF THE FIGURES

Figs. 1a and 1b schematically depict a reaction scheme for synthesis of compounds according to the invention.

00619584-01900

DETAILED DESCRIPTION OF THE INVENTION--


IN THE CLAIMS

Page 62, line 1, please delete "CLAIMS" and insert:

--WHAT IS CLAIMED IS:--

Please cancel Claims 1-11, and add Claims 12-32 as follows:






- 12. A bicyclic aromatic compound, having the general formula (I):




wherein,

- R₁ represents
- (i) the -CH₃ radical
 - (ii) the radical -CH₂OR₅, or
 - (iii) the radical -COR₆

- Ar is a radical of a formula selected from formulae (a) - (e):



- X represents



or



- R₂ and R₃, which may be identical or different, represent

(i) a hydrogen atom,

(ii) an alkyl radical having at least 3 carbon atoms, among which the carbon attached to the phenyl radical is substituted with at least two carbon atoms,

(iii) a radical $-OR_5$,

(iv) a radical $-SR_5$,

with the proviso that R_2 and R_3 , taken together, may form with the adjacent aromatic ring a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom,

with the further proviso that R_2 and R_3 cannot at the same time have the meanings (i), (iii) and (iv),

- R_4 and R_7 , which may be identical or different, represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms or a radical $-OR_5$,


- R_5 represents a hydrogen atom, a lower alkyl radical or a radical $-COR_{10}$

- R_6 represents:

(a) a hydrogen atom

(b) a lower alkyl radical

(c) a radical of formula:



or (d) a radical $-OR_{11}$

- R_8 and R_9 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R_{10} represents a lower alkyl radical,

- R_{11} represents a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, and alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, a sugar residue or an amino acid or peptide residue,

- R' and R'' , which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or sugar residue, or alternatively, taken together form a heterocycle,

a salt thereof or an optical or geometrical isomer thereof.

13. A compound according to Claim 12, selected from the group consisting of alkali metal, alkaline-earth metal, zinc and organic amine salts.

14. A compound according to Claim 12, selected from the group consisting of:


-5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene- acrylic acid,

-5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propionic acid,

-2-(3tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid,
-4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,
-5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic
acid,
-4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic
acid,
-4-(5-6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid,
-5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic
acid,
- N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl -2-naphthyl)-2-
pyrroleacrylic acid,
- N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-
pyrroleacrylic acid,
- 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
- 3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid,
- 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-pyridineacrylic acid,
and
- 6-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl) -2-pyridineacrylic
acid.

15. A compound according to Claim 12, having at least one of the following groups:

- R_1 represents the radical $-COR_6$;
- Ar represents a radical of formula (a) or (d);
- X represents the radical:



- R_2 and R_3 , taken together, form with the adjacent aromatic ring a 5- or 6-membered ring, optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulfur atom.

16. A compound according to Claim 12, suitable for use as a medicinal product for the treatment of dermatological complaints associated with a keratinization disorder which has an effect on differentiation and on proliferation.

17. A compound according to Claim 12, which is suitable for use as a medicinal agent for treatment of insulin-dependent diabetes.

18. A compound according to Claim 12, which is suitable for treatment of or inhibition of symptoms leading to a condition selected from the group consisting of common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne, secondary acne, ichthyosis, ichthyosiform states, Darier's disease, palmoplantar keratoderma, leucoplasias, leucoplasiform states, cutaneous or mucous (buccal) lichen, dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component, psoriasis, psoriatic rheumatism, cutaneous atopy, eczema, respiratory atopy, gingival hypertrophy, benign or malignant inflammatory complaints which show no keratinization disorder, dermal or epidermal hyperproliferations, common warts, flat warts and verruciform epidermodysplasia, basocellular and spinocellular epithelioma, bullosis, collagen diseases, ophthalmological disorders, aging of the skin, actinic keratoses and pigmentations, pathologies associated with chronological or actinic ageing, stigmata of epidermal and/or dermal atrophy cicatrization disorders, vibices, cicatrization, disorders of sebaceous function, hyperseborrhoea, simple seborrhoea, cancerous and precancerous states, promyelocytary leukemia, arthritis, alopecia, dermatological complaints having an immunological component, arteriosclerosis, hypertension, insulin-independent diabetes, and skin disorders caused by exposure to UV radiation.

19. A pharmaceutical composition comprising at least one compound according to Claim 12 in a pharmaceutically acceptable support.

20. The composition of Claim 19, wherein the concentration of the at least one compound is between 0.002% and 5% by weight of the pharmaceutical composition.

21. A cosmetic composition comprising at least one compound according to Claim 12 in a cosmetically acceptable support.

22. The composition of Claim 21, wherein the concentration of the at least one compound is between 0.002% and 5% by weight of the cosmetic composition.

23. The composition of Claim 21, wherein the composition is suitable for body or hair hygiene.

24. A compound according to Claim 12, wherein Ar is a radical of formula (d).

25. A compound according to Claim 24, selected from the group consisting of :
- 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene- acrylic acid,
 - 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propionic acid,
 - 2-(3tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid,
 - 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,
 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,
 - 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,
 - 4-(5-6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid,
- and
- 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphtyl)-2-thiophenepropionic acid.

26. A compound according to Claim 12, wherein Ar is a radical of formula (e).

27. A compound according to Claim 26, selected from the group consisting of :

- N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl -2-naphthyl)-2-pyrroleacrylic acid,
- N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid, and
- 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid.

28. A compound according to Claim 12, wherein R₂ and R₃, taken together form with the adjacent aromatic ring a 6-membered ring substituted with methyl groups and being interrupted by an oxygen or sulfur atom.

29. A compound according to Claim 26, wherein the compound is:

- 3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid.

30. A compound according to Claim 12, wherein R' and R'' taken together form a heterocycle.

31. A compound according to Claim 30, wherein the compound is:
- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid
morpholide.

32. A compound according to Claim 12, wherein Ar is a radical of
formula (a), with the further proviso that if R₂ is hydrogen then R₃ does not have
meaning (ii) and if R₃ has meaning (ii) than R₂ is not hydrogen.--

REMARKS

Claims 1 to 11 have been cancelled, and rewritten as new Claims 12 to 32, in
order to better emphasize the embodiment of the invention pursued in the subject
divisional application.

Favorable consideration on the merits is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Norman H. Stepno
Registration No. 22,716

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: July 19, 2000

BICYCLIC AROMATIC COMPOUNDS


The invention relates to bicyclic aromatic compounds as novel and useful industrial products. It also relates to the use of these novel compounds in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

The compounds according to the invention have pronounced activity in the fields of cell differentiation and cell proliferation, and find applications more particularly in the topical and systemic treatment of dermatological complaints associated with a disorder of keratinization, dermatological (or other) complaints with an inflammatory and/or immunoallergic component, and dermal or epidermal proliferations, these being either benign or malignant. These compounds may also be used in the treatment of degenerative diseases of connective tissue, for combating both light-induced and chronological ageing of the skin and for treating disorders of cicatrization. They moreover find an application in the ophthalmological field, in particular in the treatment of corneopathies.

The compounds according to the invention may also be used in cosmetic compositions for body and hair hygiene.

The compounds according to the invention may be represented by the general formula (I) below:

00619584-071900





in which:


- R_1 represents (i) the $-CH_3$ radical
- (ii) the radical $-CH_2OR_5$
- (iii) the radical $-COR_6$

5 R_5 and R_6 having the meaning given below

- Ar represents a radical chosen from the radicals of formulae (a)-(e) below:



R_5 and R_7 having the meaning given below,



R_8 and R_9 having the meanings given below

- R_2 and R_3 , which may be identical or different,

10

represent

(i) a hydrogen atom,

(ii) an alkyl radical having at least
3 carbon atoms, among which the carbon attached to the
phenyl radical is substituted with at least two carbon
5 atoms,

(iii) a radical $-OR_5$,

(iv) a radical $-SR_5$,

R_5 having the meaning given below,

it being understood that R_2 and R_3 , taken together,
10 may form with the adjacent aromatic ring a 5- or
6-membered ring optionally substituted with methyl
groups and/or optionally interrupted by an oxygen or
sulphur atom,

and it being understood that R_2 and R_3 cannot at
15 the same time have the meanings (i), (iii) and (iv)
mentioned above,


- R_4 and R_7 , which may be identical or different,
represent a hydrogen atom, a halogen atom, a linear or
branched alkyl radical having from 1 to 20 carbon atoms
20 or a radical $-OR_5$,

- R_5 represents a hydrogen atom, a lower alkyl
radical or a radical $-COR_{10}$

R_{10} having the meaning given below,

- R_6 represents:

- 25 (a) a hydrogen atom
(b) a lower alkyl radical
(c) a radical of formula:



R' and R'' having the meaning given below,

(d) a radical -OR₁₁

R₁₁ having the meaning given below,

- R₉ and R₉, which may be identical or different,
5 represent a hydrogen atom or a lower alkyl radical,
- R₁₀ represents a lower alkyl radical,
- R₁₁ represents a hydrogen atom, a linear or
branched alkyl radical having from 1 to 20 carbon
atoms, an alkenyl radical, a mono- or polyhydroxyalkyl
10 radical, an optionally substituted aryl or aralkyl
radical, a sugar residue or an amino acid or peptide
residue,
- R' and R'', which may be identical or different,
represent a hydrogen atom, a lower alkyl radical, a
15 mono- or polyhydroxyalkyl radical, an optionally
substituted aryl radical or an amino acid or sugar
residue, or alternatively, taken together form a
heterocycle.

The invention is also directed towards the
20 salts of the compounds of formula (I) when R₁ represents
a carboxylic acid function and the geometrical and
optical isomers of the said compounds of formula (I).

When the compounds according to the invention
are in the form of salts, they are preferably salts of

an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.

According to the present invention, the term lower alkyl radical is understood to refer to a radical
 5 having from 1 to 12, preferably from 1 to 9, carbon atoms, advantageously the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, heptyl, nonyl, decyl and dodecyl radicals.

The expression linear alkyl radical having
 10 from 1 to 20 carbon atoms is understood to refer in particular to the methyl, ethyl, propyl, pentyl, hexyl, octyl, decyl, dodecyl, hexadecyl and octadecyl radicals.

The expression branched alkyl radical having
 15 from 1 to 20 carbon atoms is understood to refer in particular to the 2-ethylhexyl, 2-methylbutyl, 2-methylpentyl, 1-methylhexyl and 3-methylheptyl radicals.

Among the alkyl radicals having at least 3
 20 carbon atoms, where the carbon attached to the phenyl radical is substituted with at least two carbon atoms, mention may be made of the tert-butyl, isopropyl, 1,1-dimethylhexyl and 1,1-dimethyldecyl radical. Preferably, these radicals have not more than 20 carbon
 25 atoms, even more preferably not more than 12 carbon atoms. Advantageously, the radical (ii) is the tert-butyl radical.

Among the monohydroxyalkyl radicals, a

00619584-071900

radical having 2 or 3 carbon atoms, in particular a 2-hydroxyethyl, 2-hydroxypropyl or 3-hydroxypropyl radical, is preferred.

Among the polyhydroxyalkyl radicals, a
5 radical having from 3 to 6 carbon atoms and from 2 to 5 hydroxyl groups, such as the 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl or 2,3,4,5-tetrahydroxypentyl radicals or the pentaerythritol residue, is preferred.

Among the aryl radicals, a phenyl radical
10 optionally substituted with at least one halogen atom, a hydroxyl or a nitro function is preferred.

Among the aralkyl radicals, the benzyl or phenethyl radical optionally substituted with at least one halogen atom, a hydroxyl or a nitro function is
15 preferred.

Among the alkenyl radicals, a radical containing from 2 to 5 carbon atoms and having one or more ethylenic unsaturations, more particularly such as the allyl radical, is preferred.

20 The term sugar residue is understood to refer to a residue derived in particular from glucose, galactose or mannose, or alternatively from glucuronic acid.

The term amino acid residue is understood to
25 refer in particular to a residue derived from lysine, from glycine or from aspartic acid, and the term peptide residue is understood to refer more particularly to a dipeptide or tripeptide residue

006720-48567960

resulting from the combination of amino acids.

Lastly, the term heterocycle is understood to refer preferably to a piperidino, morpholino, pyrrolidino or piperazino radical optionally substituted in position 4 with a C₁-C₆ alkyl or a mono-
 5 or polyhydroxyalkyl radical as defined above.

When the radicals R₄ and R₅ represent a halogen atom, this is preferably a fluorine, bromine or chlorine atom.

10 Among the compounds of formula (I) above which fall within the scope of the present invention, mention may be made in particular of the following:

- 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,
- 15 - 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propionic acid,
- 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid,
- 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-
 20 acrylic acid,
- 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,
- 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,
- 25 - 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid,
- 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropionic acid,

006T20-4856T960

- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropionic acid,
- N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid,
- 5 - 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
- 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
- 10 - 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropionic acid,
- 2-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 15 - 2-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 2-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 20 - 2-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 2-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 25 - 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,

006T20" 4856T960

- 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 5 - 3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid,
- N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
- 10 - N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide,
- 15 - Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate,
- 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,
- 4-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 20 - 4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 4-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 25 - 4-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 4-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,

006720-48567960

- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrolein,

- 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]prop-2-en-1-ol,

5 - cis-3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,

- cis-3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,


10 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-pyridineacrylic acid,

- 3-(3-Butyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,

- 6-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyridineacrylic acid.

15 According to the present invention, the compounds of formula (I) more particularly preferred are those for which at least one, and preferably all, of the following conditions are satisfied:

- 20 - R_1 represents the radical $-COR_2$
 - Ar represents the radicals of formula (a) or (d)
 - X represents the radical



- R_2 and R_3 , taken together, form, with the adjacent aromatic ring, a 5- or 6-membered ring optionally substituted with methyl groups and/or

optionally interrupted by an oxygen or sulphur atom.

The subject of the present invention is also processes for the preparation of the compounds of formula (I), in particular according to the reaction scheme given in Figure 1.

Thus, the derivatives of formula (Ia) may be obtained (Fig. 1) from aldehyde or ketone derivatives (5) according to a Horner-type reaction with a lithium or sodium derivative of a phosphonate (7). The carbonyl compounds (5) may be obtained:

- either by a coupling reaction between a boronic acid (3) and a halo derivative (4). This reaction is carried out in the presence of a palladium catalyst, for example tetrakis(triphenylphosphine)-palladium according to the conditions described by N. Miyaura et al., Synthetic Communications (1981) 11(7), 513-519. The boronic acid derivative (3) may be obtained, for example, from the halo derivative (1) by conversion into the lithium reagent (2), followed by reaction with trimethyl borate and hydrolysis.

- or by a coupling reaction between a zinc derivative (8) and a halogenated ester derivative (9) in the presence of a catalyst, for example a palladium or a nickel derivative (NiCl_2 , dppe), followed by conversion of the ester function (10) into alcohol (11) and oxidation to aldehyde (5).

The compounds of formula (Ib) may be obtained (Fig. 1) from the acetylenic derivative (6) by reaction

005720-4356T560

with n-butyllithium and then carboxylation in the presence of CO_2 . The acetylenic compounds (6) may be obtained either:

- from aldehyde derivatives (5) (when R_2 is a hydrogen atom), by reaction with carbon tetrabromide and triphenylphosphine in order to give a 2',2'-dibromostyrene derivative which is converted into acetylenic derivative by a non-nucleophilic base such as n-butyllithium, in an aprotic solvent such as tetrahydrofuran.

- from ketone derivatives (5) (when R_2 is a lower alkyl) by a reaction sequence comprising treatment with a base such as lithium diisopropylamide and then with a dialkyl phosphate chloride and again with lithium diisopropylamide.

When R_1 represents the radical $-\text{COOH}$, the compounds are prepared by protecting R_1 with a protecting group of alkyl, allylic, benzylic or tert-butyl type.

The passage to the free form may be carried out:

- in the case of an alkyl protecting group, using sodium hydroxide or lithium hydroxide in an alcoholic solvent such as methanol, or in THF.

- in the case of an allylic protecting group, using a catalyst such as certain transition metal complexes in the presence of a secondary amine such as morpholine.

006T40-4856T960

- in the case of a benzylic protecting group, by debenzylation in the presence of hydrogen using a catalyst such as palladium-on-charcoal.

- in the case of a protecting group of tert-butyl type, using trimethylsilyl iodide.

The subject of the present invention is also, as medicinal product, the compounds of formula (I) as defined above.

Some of these compounds are active in a test which consists in identifying molecules that are RXR agonists, as described in French patent application No. 95/07301 filed on 19 June 1995 by the Applicant. This test comprises the following steps: (i) a sufficient amount of a compound which is an active ligand of at least one receptor of the steroidal/thyroidal receptor superfamily, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with RXRs, such as an RAR-agonist molecule, is applied topically to part of the skin of a mammal, (ii) a molecule capable of exhibiting RXR-agonist activity is administered systemically or topically to this same part of the mammal's skin, before, during or after step (i), and (iii) the response on that part of the mammal's skin thus treated is evaluated. Thus, the response to a topical application, to a mammal's ear, of an RAR-agonist molecule, which corresponds to an increase in the thickness of this ear, may be increased by the systemic

or topical administration of an RXR-agonist molecule. Some of the compounds according to the invention are also active in the test of differentiation of mouse embryonic teratocarcinoma cells (F9) (Cancer Research 5 43, pp. 5268, 1983) and/or in the test of inhibition of ornithine decarboxylase after induction with TPA in mice (Cancer Research 38, pp. 793-801, 1978). These tests show the activities of these compounds in the fields of cell differentiation and cell proliferation 10 respectively.

The compounds according to the invention are particularly suitable in the following fields of treatment:

- 1) For treating dermatological complaints associated 15 with a keratinization disorder which has a bearing on differentiation and on proliferation, in particular for treating common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne globata, senile acne and secondary acnes such as 20 solar, medication-related or profession-related acne.
- 2) For treating other types of keratinization disorder, in particular ichthyosis, ichthyosiform states, Darier's disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous 25 or mucous (buccal) lichen.
- 3) For treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component and, in

00619584-07900

particular, all forms of psoriasis, whether it is cutaneous, mucous or ungual psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy; the compounds may also be used for some inflammatory complaints which show no keratinization disorder,

4) For treating all dermal or epidermal hyperproliferations, whether benign or malignant and whether they are of viral origin or otherwise, such as common warts, flat warts and verruciform epidermodysplasia, it being possible for the oral or florid papillomatoses and the hyperproliferations to be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma,

5) For treating other dermatological disorders such as bullosis and collagen diseases,

6) For treating certain ophthalmological disorders, in particular corneopathies,

7) For repairing or combating ageing of the skin, whether this is light-induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing,

8) For preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy,

00619584-01900

9) For preventing or treating cicatrization disorders or for preventing or repairing vibices,

10) For combating disorders of sebaceous functioning such as the hyperseborrhoea of acne or simple

5 seborrhoea,

11) In the treatment or prevention of cancerous or precancerous states,

12) In the treatment of inflammatory complaints such as arthritis,

10 13) In the treatment of any general or skin complaint of viral origin,

14) In the prevention or treatment of alopecia,

15) In the treatment of dermatological or general complaints having an immunological component,

15 16) In the treatment of complaints of the cardiovascular system such as arteriosclerosis or hypertension, as well as insulin-independent diabetes,

17) In the treatment of skin disorders caused by exposure to UV radiation.

20 In the therapeutic fields mentioned above, the compounds according to the invention may advantageously be employed in combination with other compounds having retinoid-type activity, with D vitamins or derivatives thereof, with corticosteroids, 25 with anti-free-radical agents, α -hydroxy or α -keto acids or derivatives thereof, or alternatively with ion-channel blockers. The expression D vitamins or derivatives thereof is understood to refer, for

00610584.071900

example, to vitamin D₂ or D₃ derivatives and in particular 1,25-dihydroxy vitamin D₃. The expression anti-free-radical agent is understood to refer, for example, to α -tocopherol, superoxide dismutase, ubiquinol or certain metal-chelating agents. The expression α -hydroxy or α -keto acids or derivatives thereof is understood to refer, for example, to lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid or salts, amides or esters thereof. Lastly, the expression ion-channel blockers is understood to refer, for example, to Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and derivatives thereof.

The subject of the present invention is also medicinal compositions containing at least one compound of formula (I) as defined above, one of the optical or geometric isomers thereof or one of the salts thereof.

The subject of the present invention is thus a novel medicinal composition intended in particular for treating the abovementioned complaints, and which is characterized in that it comprises, in a pharmaceutically acceptable support which is compatible with the mode of administration selected for this composition, at least one compound of formula (I), one of the optical or geometric isomers thereof or one of the salts thereof.

The compounds according to the invention may be administered enterally, parenterally, topically or

00619584-071900

ocularly.

Via the enteral route, the medicinal products may be in the form of tablets, gelatin capsules, sugar-coated tablets, syrups, suspensions, solutions,

5 powders, granules, emulsions, microspheres or nanospheres or polymeric or lipid vesicles which allow controlled release. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection.

10 The compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, taken in 1 to 3 doses.

Via the topical route, the pharmaceutical
15 compositions based on compounds according to the invention are more particularly intended for treating the skin and mucous membranes and may, in this case, be in the form of ointments, creams, milks, salves, powders, impregnated pads, solutions, gels, sprays,
20 lotions or suspensions. They may also be in the form of microspheres or nanospheres or polymeric or lipid vesicles or polymeric patches and hydrogels which allow controlled release. These topical-route compositions may moreover be either in anhydrous form or in an
25 aqueous form, depending on the clinical indication.

Via the ocular route, they are mainly eyedrops.

The compositions for topical or ocular use

00619584-071900

contain at least one compound of formula (I) defined above, or one of the optical or geometric isomers thereof, or alternatively one of the salts thereof, at a concentration preferably of between 0.001% and 5% by weight relative to the total weight of the composition.

The compounds of formula (I) according to the invention also find an application in the cosmetic field, in particular in body and hair hygiene and especially for treating skin-types with a tendency towards acne, for promoting the regrowth of the hair, for combating hair loss, for controlling the greasy appearance of the skin or the hair, in protection against the harmful effects of sunlight or in the treatment of physiologically dry skin-types, and for preventing and/or combating light-induced or chronological ageing.

In the cosmetic field, the compounds according to the invention may also advantageously be employed in combination with other compounds having retinoid-type activity, with D vitamins or derivatives thereof, with corticosteroids, with anti-free-radical agents, α -hydroxy or α -keto acids or derivatives thereof, or alternatively with ion-channel blockers, all of these different products being as defined above.

The present invention is this also directed towards a cosmetic composition which is characterized in that it comprises, in a cosmetically acceptable support which is suitable for topical application, at

least one compound of formula (I) as defined above, or one of the optical or geometric isomers thereof or one of the salts thereof, it being possible in particular for this cosmetic composition to be in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres or polymeric or lipid vesicles, a soap or a shampoo.

The concentration of compound of formula (I) in the cosmetic compositions according to the invention is advantageously between 0.001% and 3% by weight relative to the composition as a whole.

The medicinal and cosmetic compositions according to the invention may also contain inert additives or even pharmacodynamically or cosmetically active additives or combinations of these additives and, in particular, wetting agents; depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; emollients; moisturizing agents such as glycerol, PEG 400, thiamorpholinone and derivatives thereof, or urea; anti-seborrhoea or anti-acne agents such as S-carboxymethylcysteine, S-benzylcysteamine, the salts and the derivatives thereof, or benzoyl peroxide; antibiotics such as erythromycin and esters thereof, neomycin, clindamycin and esters thereof, and tetracyclines; antifungal agents such as ketoconazole or 4,5-polymethylene-3-isothiazolidones; agents for promoting the regrowth of the hair, such as minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and

derivatives thereof, diazoxide (7-chloro-3-methyl-1,2,4-benzothiadiazine 1,1-dioxide) and phenytoin (5,4-diphenylimidazolidine-2,4-dione); non-steroidal anti-inflammatory agents; carotenoids and, in particular, b-carotene; anti-psoriatic agents such as anthraline and derivatives thereof and, lastly, eicosa-5,8,11,14-tetraynoic acid and eicosa-5,8,11-triynoic acid, the esters and the amides thereof.

The compositions according to the invention may also contain flavour-enhancing agents, preserving agents such as para-hydroxybenzoic acid esters, stabilizing agents, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifying agents, UV-A and UV-B screening agents, and antioxidants such as α -tocopherol, butylhydroxyanisole or butylhydroxytoluene.

Several examples of the production of active compounds of formula (I) according to the invention, as well as various solid formulations based on such compounds, will now be given by way of illustration and with no limitation. In the preceding description and the following examples, percentages are given by weight unless otherwise stated.

EXAMPLE 1

5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid

(a) Methyl 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxylate

006T20"4856T960

00619584-071900

A solution of 2 g (8.2 mmol) of 3-tert-butyl-4-methoxybromobenzene is added dropwise to a suspension of 300 mg (12 mmol) of magnesium in 10 ml of THF. Once the addition is complete, the mixture is refluxed for one hour. At room temperature, 1.35 g (9.9 mmol) of anhydrous zinc chloride are added and the mixture is stirred for one hour. 1.2 g (5.5 mmol) of methyl 5-bromo-2-thiophenecarboxylate and 60 mg (0.12 mmol) of the $\text{NiCl}_2/\text{DPPE}$ complex are then added successively and the mixture is left stirring at room temperature for 12 hours. The reaction medium is poured into ice-water and extracted with ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is chromatographed on a column of silica eluted with a mixture of hexane and dichloromethane (50/50% by volume). After evaporation of the solvents, 1.56 g (93%) of the expected methyl ester are collected, with a melting point of 94-5°C.

(b) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-methanol

1.5 g (5 mmol) of the above methyl ester and 50 ml of anhydrous THF are introduced into a three-necked flask under a stream of nitrogen. 280 mg (7.4 mmol) of lithium aluminium hydride are added and the mixture is refluxed for four hours. It is hydrolyzed with potassium sodium tartrate solution, the salt is filtered off and the filtrate is evaporated.

The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and hexane (70/30% by volume). After evaporation of the solvents, 1.26 g (92%) of the expected alcohol are recovered, in the form of a colourless oil.

(c) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-carboxaldehyde

7.15 g (19 mmol) of pyridinium dichromate and 350 ml of dichloromethane are introduced into a round-bottomed flask. A solution of 3.9 g (14 mmol) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenemethanol in 50 ml of dichloromethane is added dropwise, at 0°C, and the mixture is stirred at room temperature for two hours. The reaction medium is filtered through silica and, after evaporation, 3.26 g (84%) of the expected aldehyde are recovered, in the form of a brown oil.

(d) Ethyl 5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylate

200 mg (6.6 mmol) of sodium hydride (80% in oil) and 50 ml of dimethoxyethane are introduced into a three-necked flask under a stream of nitrogen and a solution of 1.3 ml (6.6 mmol) of triethyl phosphoacetate in 10 ml of dimethoxyethane is added dropwise. The mixture is stirred at room temperature for one hour and then, at 0°C, a solution of 1.5 g (5.5 mmol) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde in 20 ml of dimethoxyethane

is added dropwise. The reaction medium is stirred at room temperature for four hours and is then poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and hexane (30/70% by volume); 1.88 g (100%) of the expected ethyl ester are collected, in the form of a brown oil.

(e) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid

1.88 g (5.4 mmol) of the above ethyl ester, 20 ml of methanol and 1.88 g (47 mmol) of sodium hydroxide are introduced into a round-bottomed flask and the mixture is refluxed for four hours. The reaction medium is evaporated to dryness, the residue is taken up in water and acidified to pH 1, and the solid is filtered off and dried. The solid obtained is recrystallized from ethanol, filtered off and dried. 1.09 g (63%) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylic acid are collected, with a melting point of 218-9°C.

EXAMPLE 2

5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propionic acid

(a) 2',2'-Dibromo-5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneethylene

00619584 071900

1.79 g (6.5 mmol) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde prepared in Example 1 (c) and 50 ml of dichloromethane are introduced into a round-bottomed flask. 4.32 g (13 mmol) of carbon tetrabromide, 3.41 g (13 mmol) of triphenylphosphine and 850 mg (13 mmol) of zinc powder are successively added and the mixture is stirred at room temperature for two hours. The reaction medium is evaporated and the residue obtained is purified by chromatography on a column of silica eluted with dichloromethane. 2.5 g (89%) of the expected product are collected.

(b) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acetylene

2.48 g (5.7 mmol) of 2',2'-dibromo-5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneethylene and 40 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 5.1 ml (12.7 mmol) of n-butyllithium solution (2.5 M in hexane) are added dropwise, at -78°C, and the mixture is allowed to return to room temperature over one hour. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with heptane. 1.1 g (71%) of the expected acetylenic derivative are collected, in the form of a yellow oil.

(c) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-
propionic acid

1.1 g (4 mmol) of the above acetylenic
derivative and 20 ml of THF are introduced into a
5 three-necked flask under a stream of nitrogen. 1.95 ml
(4.9 mmol) of n-butyllithium (2.5 M in hexane) are
added dropwise, at -78°C, and the mixture is stirred
for thirty minutes. A stream of CO₂ is passed through at
-78°C for fifteen minutes and the mixture is allowed to
10 return to room temperature. The reaction medium is
poured into aqueous ammonium chloride solution and
extracted with ethyl ether, and the organic phase is
separated out after settling has taken place, dried
over magnesium sulphate and evaporated. The residue
15 obtained is purified by chromatography on a column of
silica eluted with dichloromethane. After evaporation
of the solvents, 300 mg (23%) of 5-(3-tert-butyl-
4-methoxyphenyl)-2-thiophenepropionic acid are
collected, with a melting point of 124-6°C.

20 EXAMPLE 3

2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-
acrylic acid

(a) 3-tert-Butyl-4-methoxyphenylboronic acid

4 g (16.5 mmol) of 3-tert-butyl-4-methoxy-
25 bromobenzene and 50 ml of THF are introduced into a
three-necked flask under a stream of nitrogen. 7.9 ml
(19.8 mmol) of n-butyllithium (2.5 M in hexane) are
added dropwise at -78°C, the mixture is stirred for

00619584-071900

15 minutes at this temperature, 5.6 ml (49.5 mmol) of trimethyl borate are added and the mixture is stirred for 2 hours. 20 ml of hydrochloric acid (1 N) are added at -50°C and the mixture is allowed to return to room temperature. The reaction medium is extracted with ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 3.79 g (100%) of the expected boronic acid are collected, which is used in its present state for the rest of the synthesis.

(b) Ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxylate

260 mg (0.5 mmol) of tetrakis(triphenylphosphine)palladium(0), 50 ml of toluene and 2.59 g (10.9 mmol) of ethyl 2-bromo-4-thiophenecarboxylate are introduced into a three-necked flask under a stream of nitrogen and the mixture is stirred at room temperature for 20 minutes. 3.7 g (16.5 mmol) of 3-tert-butyl-4-methoxyphenylboronic acid and 11 ml of aqueous sodium carbonate solution (2 N) are then added and the mixture is refluxed for 8 hours. The reaction medium is evaporated to dryness, the residue is taken up in water and ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue is purified by chromatography on a column of silica eluted with a mixture of ethyl acetate and heptane (10/90% by volume). 3.53 g (69%) of ethyl 2-(3-tert-butyl-

4-methoxyphenyl)-4-thiophenecarboxylate are obtained.

(c) 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-
methanol

In a similar manner to Example 1(b), starting
5 with 3.5 g (11 mmol) of ethyl 2-(3-tert-butyl-
4-methoxyphenyl)-4-thiophenecarboxylate, 3.2 g (100%)
of the expected alcohol are obtained in the form of a
brown oil.

(d) 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-
10 carboxaldehyde

In a similar manner to Example 1(c), starting
with 3.2 g (11 mmol) of the above alcohol, 2.3 g (76%)
of 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophene-
carboxaldehyde are obtained in the form of a brown oil.

(e) Ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophene-
15 acrylate

In a similar manner to Example 1(d), by
reaction of 1.3 g (4.7 mmol) of 2-(3-tert-butyl-
4-methoxyphenyl)-4-thiophenecarboxaldehyde with 1.28 g
20 (5.7 mmol) of triethyl phosphonoacetate, 1.1 g (67%) of
the expected ethyl ester are obtained, with a melting
point of 119-20°C.

(f) 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-
acrylic acid

25 In a similar manner to Example 1(e), starting
with 1.1 g (3.2 mmol) of the above ethyl ester, 750 mg
(74%) of 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophene-
acrylic acid are obtained, with a melting point of

00619584-071900

197-8°C.

EXAMPLE 4

4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-
acrylic acid

- 5 (a) 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-
carboxaldehyde

In a similar manner to Example 3(b), by
reaction of 2.68 g (12.3 mmol) of 3-tert-butyl-
4-methoxyphenylboronic acid with 1.55 g (2.12 mmol) of
10 4-bromo-2-thiophenecarboxaldehyde, 2.13 g (95%) of
4-(3-tert-butyl-4-methoxyphenyl)-2-thiophene-
carboxaldehyde are obtained in the form of a yellow
oil.

- (b) Ethyl 4-(3-tert-butyl-4-methoxyphenyl)-
15 2-thiopheneacrylate

In a similar manner to Example 1(d), by
reaction of 1.2 g (4.3 mmol) of 4-(3-tert-butyl-
4-methoxyphenyl)-2-thiophenecarboxaldehyde with 1.17 g
(5.2 mmol) of triethyl phosphonoacetate, 1.55 g (100%)
20 of the expected ethyl ester are obtained in the form of
an oil.

- (c) 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-
acrylic acid

In a similar manner to Example 1(e), starting
25 with 1.55 g (4.5 mmol) of the above ethyl ester, 1.14 g
(88%) of 4-(3-tert-butyl-4-methoxyphenyl)-2-thiophene-
acrylic acid are obtained, with a melting point of
206-7°C.

00619584.071900

EXAMPLE 55-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid

- 5 (a) 3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid,

In a similar manner to Example 3(a), starting with 5 g (17.8 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-bromonaphthalene, 4.22 g (100%) of boronic acid are obtained.

- 10 (b) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenecarboxaldehyde

In a similar manner to Example 3(b), by reaction of 4.2 g (17 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 2.17 g (11.3 mmol) of 5-bromo-2-thiophenecarboxaldehyde, 2.1 g (60%) of the expected aldehyde are obtained, with a melting point of 130-5°C.

- 15 (c) Ethyl 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylate

20 In a similar manner to Example 1(d), by reaction of 2 g (6.4 mmol) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenecarboxaldehyde with 1.73 g (7.7 mmol) of triethyl phosphonoacetate, 2.02 g (82%) of the expected ethyl ester are obtained.

- 25 (e) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid

In a similar manner to Example 1(e), starting

with 2 g (5.2 mmol) of the above ethyl ester, 1.79 g (96%) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid are obtained, with a melting point of 175-7°C.

5 EXAMPLE 6

4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid

(a) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenecarboxaldehyde

10 In a similar manner to Example 3(b), by reaction of 4.2 g (17 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 2.17 g (11.3 mmol) of 4-bromo-2-thiophenecarboxaldehyde, 2.75 g (78%) of the expected aldehyde are obtained, 15 with a melting point of 144-6°C.

(b) Ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylate

In a similar manner to Example 1(d), by reaction of 2.7 g (8.6 mmol) of 4-(3,5,5,8,8-penta- 20 methyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-carboxaldehyde with 2.1 ml (10.4 mmol) of triethyl phosphonoacetate, 2.76 g (84%) of the expected ethyl ester are obtained.

(c) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro- 25 2-naphthyl)-2-thiopheneacrylic acid

In a similar manner to Example 1(e), starting with 2.7 g (7.1 mmol) of the above ethyl ester, 2.5 g (98%) of 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-

00619584-01900
006T20-4856T960

2-naphthyl)-2-thiopheneacrylic acid are obtained, with a melting point of 215-20°C.

EXAMPLE 7

5 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid

(a) 5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid

10 In a similar manner to Example 3(a), starting with 5 g (18.7 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-bromonaphthalene, 4.3 g (100%) of the expected boronic acid are obtained.

(b) 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiophenecarboxaldehyde

15 In a similar manner to Example 3(b), by reaction of 4.3 g (18.7 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid with 2.36 g (12.3 mmol) of 4-bromo-2-thiophenecarboxaldehyde, 2.3 g (63%) of the expected aldehyde derivative are obtained, with a melting point of 84-5°C.

20 (c) Ethyl 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylate

25 In a similar manner to Example 1(d), by reaction of 2.28 g (8.3 mmol) of (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiophenecarboxaldehyde with 2 ml (9.9 mmol) of triethyl phosphonoacetate, 810 mg (26%) of the expected ethyl ester are obtained, with a melting point of 82-4°C.

(d) 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-

00619584-071900

2-naphthyl)-2-thiopheneacrylic acid

In a similar manner to Example 1(e), starting with 810 mg (2.2 mmol) of the above ethyl ester, 720 mg (96%) of 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid are obtained, with a melting point of 182-5°C.

EXAMPLE 8

5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid

- 10 (a) 2',2'-Dibromo-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneethylene

In a similar manner to Example 2(a), starting with 3 g (9.6 mmol) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-15 carboxaldehyde, 4.56 g (100%) of 2',2'-dibromo-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneethylene are obtained.

- (b) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacetylene

- 20 In a similar manner to Example 2(b), starting with 4.5 g (9.6 mmol) 2',2'-dibromo-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneethylene, 1.42 g (48%) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-25 acetylene are obtained.

- (c) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid

In a similar manner to Example 2(c), starting

with 1.4 g (4.5 mmol) of the above acetylenic derivative, 800 mg (51%) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid are obtained, with a melting point of 138-40°C.

5 EXAMPLE 9

3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropionic acid

(a) 3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid,

10 100 g (0.356 mol) of 2-bromo-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalene and 1 litre of THF are introduced into a two-litre reactor under a stream of nitrogen, and the solution is cooled to -60°C. 157 ml (0.392 mol) of n-butyllithium (2.5 M in
15 hexane) are added dropwise and the mixture is stirred for one hour. 121 ml (1.07 mol) of trimethyl borate are added dropwise at -70°C and the mixture is stirred for one hour. 500 ml of hydrochloric acid (1 N) are added at -35°C and the mixture is allowed to return to room
20 temperature. The reaction medium is extracted with ethyl acetate and the organic phase is separated out after settling has taken place, washed twice with 500 ml of hydrochloric acid (1 N), dried over magnesium sulphate and evaporated. 83 g (95%) of the expected
25 boronic acid are collected.

(b) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde

700 ml of DME, 2.4 g (2 mmol) of

006T20"4856T960

tetrakis(triphenylphosphine)palladium(0) and 8.44 g (45.6 mmol) of 3-bromobenzaldehyde are introduced into a three-necked flask under a stream of nitrogen and the mixture is stirred for 10 minutes. A solution of 17 g (69.1 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid in 25 ml of ethanol are then added, followed by 46 ml (91 mmol) of potassium carbonate solution (2 M) and the mixture is refluxed for four hours. The reaction medium is cooled and filtered and the solid is washed with bicarbonate solution and then with ethyl acetate. The solid obtained is recrystallized from ethanol and 7 g (50%) of the expected aldehyde are collected, with a melting point of 104-5°C.

- 15 (c) 2',2'-Dibromo-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylethylene

In a similar manner to Example 2(a), starting with 2 g (6.5 mmol) of the above aldehyde, 1.96 g (65%) of the expected product are obtained in the form of a colourless oil.

- 20 (d) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacetylene

In a similar manner to Example 2(b), starting with 1.96 g (4.23 mmol) of 2',2'-dibromo-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylethylene, 1.29 g (99%) of the expected acetylenic derivative are obtained in the form of a pale yellow oil.

(e) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropionic acid

In a similar manner to Example 2(c), starting with 1.17 g (3.9 mmol) of the above acetylenic derivative, 900 mg (67%) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropionic acid are obtained, with a melting point of 180-1°C.

EXAMPLE 10

N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid

(a) 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde

In a similar manner to Example 3(b), by reaction of 5.9 g (25.6 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid with 3.7 g (21.3 mmol) of 4-bromo-2-pyrrolecarboxaldehyde, 1.3 g (21.6%) of the expected product are obtained, with a melting point of 211-2°C.

(b) N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde

1.3 g (4.6 mmol) of 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde and 50 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 300 mg (10 mmol) of sodium hydride (80% in oil) are added portionwise and the mixture is stirred until the evolution of gas has ceased. 640 μ l (10 mmol) of iodomethane are then added and the mixture is stirred at room temperature for one

hour. The reaction medium is poured into water and extracted with ethyl acetate, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue
 5 obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and heptane (70/30). After evaporation of the solvents, 600 mg (44%) of the expected product are collected.

(c) Ethyl N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylate
 10

In a similar manner to Example 1(d), by reaction of 480 mg (1.3 mmol) of N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde with 400 μ l (152 mmol) of
 15 triethyl phosphonoacetate, 350 mg of the expected ethyl ester are obtained in the form of an oil.

(d) N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid

In a similar manner to Example 1(e), starting
 20 with 350 mg (0.94 mmol) of the above ethyl ester, 170 mg (23%) of N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid are obtained, with a melting point of 185-6°C.

EXAMPLE 11

25 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid

(a) 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylcarboxaldehyde

00619584.071900

In a similar manner to Example 3(b), by reaction of 6.43 g (27.7 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid with 2.7 ml (23.1 mmol) of 4-bromobenzaldehyde, 2.05 g (24%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-phenylcarboxaldehyde are obtained in the form of a pale yellow oil.

(b) Ethyl 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylate

In a similar manner to Example 1(d), by reaction of 800 mg (2.7 mmol) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylcarboxaldehyde with 650 ml (3.3 mmol) of triethyl phosphonoacetate, 900 mg (91%) of the expected ethyl ester are obtained in the form of a colourless oil.

(c) 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid

In a similar manner to Example 1(e), starting with 1.22 g (2.7 mmol) of the above ethyl ester, 380 mg (41%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 210-1°C.

EXAMPLE 12

N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid

(a) N-Methyl-4-bromo-2-pyrrolecarboxaldehyde

In a similar manner to Example 10(b), by reaction of 4 g (23 mmol) of 4-bromo-

2-pyrrolicarboxaldehyde with 1.7 ml (27.6 mmol) of iodomethane, 2.3 g (50%) of the expected product are obtained, with a melting point of 123-4°C.

- (b) N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolicarboxaldehyde

In a similar manner to Example 3(b), by reaction of 3 g (12.1 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 1.9 g (10.1 mmol) of N-methyl-4-bromo-2-pyrrolicarboxaldehyde, 1.85 g (59%) of the expected product are obtained in the form of a pale yellow oil.

- (c) Ethyl N-methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolicacrylate

In a similar manner to Example 1(d), by reaction of 1.85 g (6 mmol) of N-methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolicarboxaldehyde with 1.4 ml (7.2 mmol) of triethyl phosphonoacetate, 2.1 g (92%) of the expected ethyl ester are obtained in the form of an orange-coloured oil.

- (d) N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolicacrylic acid

In a similar manner to Example 1(e), starting with 2 g (5.3 mmol) of the above ethyl ester, 730 mg (39.5%) of N-methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolicacrylic acid are obtained, with a melting point of 185-6°C.

EXAMPLE 134-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-
2-naphthyl)-2-pyrroleacrylic acid

- (a) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-
5 2-naphthyl)-2-pyrrolecarboxaldehyde

In a similar manner to Example 3(b), by
reaction of 2.47 g (10 mmol) of 3,5,5,8,8-pentamethyl-
5,6,7,8-tetrahydro-2-naphthylboronic acid with 1.5 g
(8.4 mmol) of 4-bromo-2-pyrrolecarboxaldehyde, 950 mg
10 (38.5%) of the expected aldehyde are obtained, with a
melting point of 128-9°C.

- (b) Ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-
2-naphthyl)-2-pyrroleacrylate

In a similar manner to Example 1(d), by
15 reaction of 500 mg (1.7 mmol) of 4-(3,5,5,8,8-
pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-
2-pyrrolecarboxaldehyde with 400 μ l (2 mmol) of
triethyl phosphonoacetate, 570 mg (92%) of the expected
ethyl ester are obtained.

- 20 (c) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-
2-naphthyl)-2-pyrroleacrylic acid

In a similar manner to Example 1(e), starting
with 570 mg (1.9 mmol) of ethyl 4-(3,5,5,8,8-
pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-
25 2-pyrroleacrylate, 240 mg (37%) of 4-(3,5,5,8,8-
pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-
2-pyrroleacrylic acid are obtained, with a melting
point of 245-6°C.

00619584-071900

EXAMPLE 143-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid

In a similar manner to Example 9(b), by
 5 reaction of 73.4 g (0.30 mol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 44.7 g (0.20 mol) of 4-bromophenylacrylic acid, and after recrystallization from ethanol, 48 g (61%) of
 10 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 207-8°C.

EXAMPLE 153-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropionic acid

15 (a) 2',2'-Dibromo-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylethylene

In a similar manner to Example 2(a), starting with 2.05 g (7 mmol) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)benzaldehyde [prepared in
 20 Example 11(a)], 1.07 g (35%) of the expected product are obtained in the form of an oil.

(b) 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropionic acid.

900 mg (2 mmol) of 2',2'-dibromo-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl-
 25 ethylene and 40 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 2.2 ml (5.2 mmol) of n-butyllithium solution (2.5 M in hexane)

are added dropwise at -50°C and the mixture is allowed to return to room temperature. CO_2 is introduced at 0°C for 20 minutes and the mixture is stirred at room temperature for one hour. The reaction medium is poured into saturated ammonium chloride solution and adjusted to pH 1 with hydrochloric acid, the mixture is extracted with ethyl acetate and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and methanol (95/5). After evaporation of the solvents, 80 mg (12%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropionic acid are collected, with a melting point of $164-5^{\circ}\text{C}$.

EXAMPLE 16

2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid

(a) 2-Hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde.

In a similar manner to Example 9(b), by reaction of 15 g (61 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 8.16 g (41 mmol) of 5-bromo-2-hydroxybenzaldehyde, 11.7 g (89%) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde are obtained, with a melting point of $138-9^{\circ}\text{C}$.

(b) 2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde.

In a similar manner to Example 10(b), by reaction of 2 g (6.2 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 425 μ l (6.8 mmol) of iodomethane, 1.68 g (88%) of the expected product are obtained.

(c) Ethyl 2-methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate.

In a similar manner to Example 1(d), by reaction of 1.65 g (5 mmol) of 2-methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 1.68 g (7.5 mmol) of triethyl phosphonoacetate, 1.7 g (83%) of the expected ethyl ester are obtained in the form of an oil.

(d) 2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

In a similar manner to Example 1(e), starting with 1.6 g (3.9 mmol) of the above ethyl ester, 1.4 g (93%) of 2-methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 181-2°C.

EXAMPLE 17

2-Propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

(a) 2-Propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde.

In a similar manner to Example 10(b), by

006T20"4856T950

reaction of 2 g (6.2 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [prepared in Example 16(a)] with 670 μ l (6.8 mmol) of 1-iodopropane, 2.2 g (88%) of the expected product are
5 obtained in the form of a colourless oil.

(b) Ethyl 2-propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate.

In a similar manner to Example 1(d), by reaction of 2.18 g (6 mmol) of 2-propyloxy-5-
10 (3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 2.03 g (9 mmol) of triethyl phosphonoacetate, 2.13 g (82%) of the expected ethyl ester are obtained in the form form of a yellow oil.

(c) 2-Propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.
15

In a similar manner to Example 1(e), starting with 2.1 g (4.8 mmol) of the above ethyl ester, 1.68 g (86%) of 2-propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained,
20 with a melting point of 125-6°C.

EXAMPLE 18

2-Heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

(a) 2-Heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde.
25

In a similar manner to Exmample 10(b), by reaction of 2 g (9.3 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde

[prepared in Example 16(a)] with 1.1 ml (6.8 mmol) of 1-bromoheptane, 1.88 g (72%) of the expected product are obtained in the form of a yellow oil.

(b) Ethyl 2-heptyloxy-5-(3,5,5,8,8-pentamethyl-
5 5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate.

In a similar manner to Example 1(d), by reaction of 1.78 g (4.2 mmol) of 2-heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 1.44 g (6.3 mmol) of
10 triethyl phosphonoacetate, 1.89 g (90%) of the expected ethyl ester are obtained in the form of a yellow oil.

(c) 2-Heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

In a similar manner to Example 1(e), starting
15 with 1.89 g (3.9 mmol) of the above ethyl ester, 1.2 g (67%) of 2-heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 137-8°C.

EXAMPLE 19

20 2-Methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

(a) 2-Methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde.

25 In a similar manner to Example 10(b), by reaction of 3 g (9.3 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [prepared in Example 16(a)] with 777 μ l (10.2 mmol) of

00619584.01900

methoxymethyl chloride, 3.5 g (100%) of the expected product are obtained in the form of an oil.

(b) Ethyl 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate.

5 In a similar manner to Example 1(d), by reaction of 3.4 g (9.3 mmol) of 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-benzaldehyde with 4.16 g (18.6 mmol) of triethyl phosphonoacetate, 3.5 g (86%) of the expected ethyl ester are obtained, with a melting point of 100-1°C.

(c) 2-Methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

15 In a similar manner to Example 1(e), starting with 1.5 g (3.4 mmol) of the above ethyl ester, 1.2 g (86%) of 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 191-2°C.

EXAMPLE 20

20 2-Hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

(a) Methyl 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate

1.9 g (4.35 mmol) of 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, 20 ml of methanol and 30 ml of THF are introduced into a round-bottomed flask. 2.8 ml of concentrated sulphuric acid are added and the mixture is stirred at room temperature for 12

006T40"4856T960

hours. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, washed with water, dried over magnesium sulphate and evaporated. 1.63 g (95%) of methyl 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate are collected.

(b) 2-Hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid.

In a similar manner to Example 1(e), starting with 1.63 g (4.25 mmol) of the above ethyl ester, 1.3 g (85%) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 204-5°C.

EXAMPLE 21

3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid.

(a) 3-Bromo-2-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene.

7 g (24.7 mmol) of 3-bromo-2-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene and 40 ml of DMF are introduced into a three-necked flask under a stream of nitrogen. 890 mg (29.6 mmol) of sodium hydride (80% in oil) are added portionwise and the mixture is stirred until the evolution of gas has ceased. 1.7 ml (27 mmol) of iodomethane are then added and the mixture is stirred at room temperature for one hour. The reaction medium is poured into water and

extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 7.3 g (99%) of the expected product are collected in the form of an oil which crystallizes slowly. Melting point 77-8°C.

(b) 2-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthylboronic acid.

In a similar manner to Example 3(a), starting with 6.7 g (22.5 mmol) of 3-bromo-2-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene, 4.54 g (77%) of the expected boronic acid are obtained, with a melting point of 151-2°C.

(c) 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid.

In a similar manner to Example 9(b), by reaction of 2.62 g (10 mmol) of 2-methoxy-5,6,7,8-tetramethylnaphthylboronic acid with 1.51 g (6.7 mmol) of 3-bromophenylacrylic acid, 1.1 g (45%) of 3-(3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 187-8°C.

EXAMPLE 22

3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid.

(a) 3-Bromo-2-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene.

In a similar manner to Example 21(a), by reaction of 7 g (24.7 mmol) of 3-bromo-2-hydroxy-

006T20-4856T950

5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene with
2.45 ml (27 mmol) of 1-bromopropane, 8.1 g (100%) of
3-bromo-2-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-
tetramethylnaphthalene are obtained in the form of an
5 orange-coloured oil.

(b) 2-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-
methylnaphthylboronic acid.

In a similar manner to Example 3(a), by
reaction of 8 g (24.6 mmol) of 3-bromo-2-propyloxy-
10 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene,
5.7 g (80%) of the expected boronic acid are obtained,
with a melting point of 138-9°C.

(c) 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-
methyl-2-naphthyl)phenylacrylic acid.

15 In a similar manner to Example 9(b), by
reaction of 5 g (17.2 mmol) of 2-propyloxy-5,6,7,8-
tetrahydro-5,5,8,8-tetramethylnaphthylboronic acid with
2.6 g (11.5 mmol) of 3-bromophenylacrylic acid, 1.66 g
(35%) of 3-(3-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-
20 tetramethyl-2-naphthyl)phenylacrylic acid are obtained,
with a melting point of 172-3°C.

EXAMPLE 23

3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-
tetramethyl-2-naphthyl)phenylacrylic acid.

25 (a) 3-Bromo-2-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-
tetramethylnaphthalene.

In a similar manner to Example 21(a), by
reaction of 7 g (24.7 mmol) of 3-bromo-2-hydroxy-

5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene with
4.24 ml (27 mmol) of 1-bromoheptane, 10 g (100%) of
3-bromo-2-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-
tetramethylnaphthalene are obtained in the form of a
5 brown oil.

(b) 2-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-
methylnaphthylboronic acid.

In a similar manner to Example 3(a), starting
with 10 g (26.2 mmol) of 3-bromo-2-heptyloxy-5,6,7,8-
10 tetrahydro-5,5,8,8-tetramethylnaphthalene, 6.1 g (67%)
of the expected boronic acid are obtained, with a
melting point of 102-3°C.

(c) 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-
methyl-2-naphthyl)phenylacrylic acid.

15 In a similar manner to Example 9(b), by
reaction of 5 g (14.4 mmol) of 2-heptyloxy-5,6,7,8-
tetrahydro-5,5,8,8-tetramethylnaphthylboronic acid with
2.52 g (11.1 mmol) of 3-bromophenylacrylic acid, 2.7 g
(54%) of 3-(3-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-
20 tetramethyl-2-naphthyl)phenylacrylic acid are obtained,
with a melting point of 112-3°C.

EXAMPLE 24

3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-
5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic
25 acid.

(a) 3-Bromo-2-methoxymethoxy-5,6,7,8-tetrahydro-
5,5,8,8-tetramethylnaphthalene.

In a similar manner to Example 21(a), by

reaction of 7 g (24.7 mmol) of 3-bromo-2-hydroxy-
 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene with
 2.05 ml (27 mmol) of methoxymethyl chloride, 8.1 g
 (100%) of 3-bromo-2-methoxymethoxy-5,6,7,8-tetrahydro-
 5,5,8,8-tetramethylnaphthalene are obtained in the form
 of a light-brown oil.

(b) 2-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-
 methylnaphthylboronic acid.

In a similar manner to Example 3(a), starting
 with 8 g (24.4 mmol) of 3-bromo-2-methoxymethoxy-
 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene,
 5.5 g (77%) of the expected boronic acid are obtained,
 with a melting point of 133-4°C.

(c) 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-
 tetramethyl-2-naphthyl)phenylacrylic acid.

In a similar manner to Example 9(b), by
 reaction of 5.3 g (18.1 mmol) of 2-methoxymethoxy-
 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthylboronic
 acid with 3.16 g (14 mmol) of 3-bromophenylacrylic acid,
 4.39 g (80%) of 3-(3-methoxymethoxy-5,6,7,8-tetrahydro-
 5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are
 obtained, with a melting point of 156-7°C.

EXAMPLE 25

3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-
 tetramethyl-2-naphthyl)phenylacrylic acid.

(a) Methyl 3-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-
 tetramethyl-2-naphthyl)phenylacrylate.

2 g (5 mmol) of 3-(3-methoxymethoxy-5,6,7,8-

tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, 10 ml of methanol and 10 ml of THF are introduced into a round-bottomed flask. 2.8 ml of concentrated sulphuric acid are added and the mixture is stirred at room temperature for 6 hours. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, washed with water, dried over magnesium sulphate and evaporated. 1.80 g (98%) of the expected methyl ester are collected, with a melting point of 182-3°C.

(b) 3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid.

In a similar manner to Example 1(e), starting with 1.5 g (4.1 mmol) of the above methyl ester, 1.3 g (90%) of 3-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 244-5°C.

EXAMPLE 26

3-(4,4,7-Trimethylthiochroman-6-yl)phenylacrylic acid.

(a) 1-Methyl-3-(3-methylbut-2-enyl)sulphanylbenzene.

5 g (40 mmol) of 3-methylthiophenol, 5.6 g (40 mmol) of potassium carbonate and 50 ml of DMF are introduced into a three-necked flask. 7.2 g (48 mmol) of 3-methyl-2-butene bromide are added and the mixture is stirred at room temperature for four hours. The

reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 7.8 g (100%) of the expected product are collected in the form of a yellow oil.

(b) 4,4,7-Trimethylthiochroman.

7 g (36.4 mmol) of 1-methyl-3-(3-methylbut-2-enyl)sulphanylbenzene and 50 ml of toluene are introduced into a round-bottomed flask and 10.4 g (54.6 mmol) of para-toluenesulphonic acid are added. The mixture is refluxed for four hours. The reaction medium is evaporated to dryness, the residue is taken up in water and ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 6.8 g (97%) of the thiochroman are collected in the form of a brown oil.

(c) 6-Bromo-4,4,7-trimethylthiochroman.

6.2 g (32.2 mmol) of 4,4,7-trimethylthiochroman, 40 ml of dichloromethane and 90 mg of iron powder are introduced into a three-necked flask. 1.65 ml (32.2 mmol) of bromine are added and the mixture is stirred at room temperature for two hours. The reaction medium is poured into sodium bicarbonate solution and extracted with dichloromethane, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a

column of silica eluted with heptane. 5.9 g (67%) of the bromo derivative are collected in the form of a pale yellow oil.

(d) 4,4,7-Trimethylthiochromanylboronic acid.

5 In a similar manner to Example 3(a), starting with 5.8 g (21.4 mmol) of 6-bromo-4,4,7-trimethylthiochroman, 3.88 g (76%) of the expected boronic acid are obtained, with a melting point of 252-3°C.

(e) 3-(4,4,7-Trimethylthiochroman-6-yl)phenylacrylic acid.
10

In a similar manner to Example 9(b), by reaction of 1.5 g (6.3 mmol) of 4,4,7-trimethylthiochromanylboronic acid with 1.2 g (5.3 mmol) of 3-bromophenylacrylic acid, 1.1 g (99%) of 3-(4,4,7-trimethylthiochroman-6-yl)phenylacrylic acid are
15 obtained, with a melting point of 102-3°C.

EXAMPLE 27

N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide.

20 (a) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacryloyl chloride.

3.5 g (10 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid and 50 ml of dichloromethane are introduced into a round-bottomed flask and 2 ml (10 mmol) of dicyclohexylamine are added. The mixture is stirred at room temperature
25 for 10 minutes and 729 μ l (10 mmol) of thionyl chloride

00610584.071000

are then introduced with stirring for 15 minutes. The reaction medium is evaporated to dryness, the residue is taken up in ethyl ether, the dicyclohexylamine salt is filtered off and the filtrate is evaporated. 3.7 g (100%) of the crude acid chloride are collected, which will be used in its current state for the rest of the synthesis.

(b) N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide.

20 ml of THF are introduced into a round-bottomed flask and 2.8 ml (35 mmol) of ethylamine solution (70%) are added. A solution of 1.2 g (3.2 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacryloyl chloride in 40 ml of THF is added dropwise and the mixture is stirred at room temperature for one hour. The reaction medium is acidified with hydrochloric acid and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with dichloromethane. After evaporation of the solvents, 817 mg (68%) of N-ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylamide are collected, with a melting point of 158-9°C.

EXAMPLE 28

N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylamide.

5 In a similar manner to Example 27(a), by
reaction of 1.2 g (3.2 mmol) of 3-(3,5,5,8,8-penta-
methyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacryloyl
chloride with 349 mg (3.2 mmol) of 4-hydroxyaniline,
810 mg of (57%) of N-(4-hydroxyphenyl)-3-(3,5,5,8,8-
10 pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl-
acrylamide are obtained, with a melting point of
240-1°C.

EXAMPLE 29

15 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide.

 In a similar manner to Example 27(a), by
reaction of 1.3 g (3.4 mmol) of 3-(3,5,5,8,8-penta-
methyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacryloyl
chloride with 620 µl of (7.12 mmol) of morpholine,
20 1.25 g (88%) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-
tetrahydro-2-naphthyl)phenylacrylic acid morpholide are
obtained, with a melting point of 158-9°C.

00619584.071000

EXAMPLE 30

Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate.

In a similar manner to Example 1(d), by
5 reaction of 5 g (16.3 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 4.79 g (21.2 mmol) of triethyl phosphonoacetate, 5 g (81%) of ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate are obtained, with
10 a melting point of 70-2°C.

EXAMPLE 31

3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid.

(a) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)acetophenone.
15

In a similar manner to Example 9(b), by
reaction of 5 g (20.3 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 2.7 g (13.5 mmol) of 3-bromoacetophenone, 4.3 g (90%) of the
20 expected product are obtained, with a melting point of 89-90°C.

(b) Ethyl 3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoate.

In a similar manner to Example 1(d), by
25 reaction of 3.7 g (11.5 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)acetophenone with 3.9 g (17.3 mmol) of triethyl phosphonoacetate, 2.67 g (60%) of the expected ethyl ester are obtained

00619584.071900

in the form of a yellow oil.

(c) 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid.

In a similar manner to Example 1(e), starting with 2.5 g (6.4 mmol) of the above ethyl ester, 1.63 g (70%) of 3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid are obtained, with a melting point of 166-7°C.

EXAMPLE 32

Various solid formulations based on compounds according to the invention are illustrated in this example.

A- ORAL ROUTE

(a) 0.2 g tablet

15	- Compound of Example 1	0.001 g
	- Starch	0.114 g
	- Dicalcium phosphate	0.020 g
	- Silica	0.020 g
	- Lactose	0.030 g
20	- Talc	0.010 g
	- Magnesium stearate	0.005 g

(b) Drinkable suspension in 5 ml ampoules

	- Compound of Example 3	0.001 g
	- Glycerol	0.500 g
25	- 70% Sorbitol	0.500 g
	- Sodium saccharinate	0.010 g
	- Methyl para-hydroxybenzoate	0.040 g
	- Flavouring qs	

006T20"4856T960

- Purified water qs 5 ml

(c) 0.8 g tablet

- Compound of Example 5 0.500 g

- Pregelatinized starch 0.100 g

5 - Microcrystalline cellulose 0.115 g

- Lactose 0.075 g

- Magnesium stearate 0.010 g

(d) Drinkable suspension in 10 ml ampoules

- Compound of Example 2 0.050 g

10 - Glycerol 1.000 g

- 70% Sorbitol 1.000 g

- Sodium saccharinate 0.010 g

- Methyl para-hydroxybenzoate 0.080 g

- Flavouring qs

15 - Purified water qs 10 ml

B- TOPICAL ROUTE

(a) Ointment

- Compound of Example 21 0.020 g

- Isopropyl myristate 81.700 g

20 - Liquid petroleum jelly 9.100 g

- Silica ("Aerosil 200" sold by
Degussa) 9.180 g

(b) Ointment

- Compound of Example 9 0.300 g

25 - White petroleum jelly codex qs 100 g

006T40" 4856T960

(c) Nonionic water-in-oil cream

	- Compound of Example 7	0.100 g
	- Mixture of emulsifying lanolin alcohols, waxes and oils ("Anhydrous Eucerin" sold by BDF)	39.900 g
5	- Methyl para-hydroxybenzoate	0.075 g
	- Propyl para-hydroxybenzoate	0.075 g
	- Sterile demineralized water qs	100 g

(d) Lotion

10	- Compound of Example 30	0.100 g
	- Polyethylene glycol (PEG 400)	69.900 g
	- 95% Ethanol	30.000 g

(e) Hydrophobic ointment

	- Compound of Example 25	0.300 g
15	- Isopropyl myristate	36.400 g
	- Silicone oil ("Rhodorsil 47 V 300" sold by Rhône-Poulenc)	36.400 g
	- Beeswax	13.600 g
	- Silicone ("Abil 300,000 cst" sold by Goldschmidt) qs	100 g
20		

(f) Nonionic oil-in-water cream

	- Compound of Example 14	0.500 g
	- Cetyl alcohol	4.000 g
	- Glyceryl monostearate	2.500 g
25	- PEG 50 stearate	2.500 g
	- Karite butter	9.200 g
	- Propylene glycol	2.000 g
	- Methyl para-hydroxybenzoate	0.075 g


006720-48567960

- Propyl para-hydroxybenzoate 0.075 g
- Sterile demineralized water qs 100 g

006T20-4856T960

CLAIMS

1. Bicyclic aromatic compounds,
characterized in that they correspond to the general
formula (I) below:





5 in which:

- R_1 represents (i) the $-CH_3$ radical
- (ii) the radical $-CH_2OR_5$,
- (iii) the radical $-COR_6$


R_5 and R_6 having the meaning given below

10 - Ar represents a radical chosen from the radicals
of formulae (a)-(e) below:



R_5 and R_7 having the meaning given below,

- X represents



R₂ and R₃ having the meanings given below

- R₂ and R₃, which may be identical or different,
5 represent

(i) a hydrogen atom,

(ii) an alkyl radical having at least
3 carbon atoms, among which the carbon attached to the
phenyl radical is substituted with at least two carbon
10 atoms,

(iii) a radical -OR₅,

(iv) a radical -SR₅,

R₅ having the meaning given below,

it being understood that R₂ and R₃, taken together,
15 may form with the adjacent aromatic ring a 5- or
6-membered ring optionally substituted with methyl
groups and/or optionally interrupted by an oxygen or
sulphur atom,

and it being understood that R₂ and R₃ cannot at
20 the same time have the meanings (i), (iii) and (iv)
mentioned above,

- R₄ and R₇, which may be identical or different,
represent a hydrogen atom, a halogen atom, a linear or
branched alkyl radical having from 1 to 20 carbon atoms

006T20-4956T960


or a radical $-OR_5$,

- R_5 represents a hydrogen atom, a lower alkyl radical or a radical $-COR_{10}$

R_{10} having the meaning given below,

5 - R_6 represents:

- (a) a hydrogen atom
- (b) a lower alkyl radical
- (c) a radical of formula:



R' and R'' having the meaning given below,

10 (d) a radical $-OR_{11}$

R_{11} having the meaning given below,

- R_8 and R_9 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R_{10} represents a lower alkyl radical,

15 - R_{11} represents a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, a sugar residue or an amino acid or peptide residue,

20

- R' and R'' , which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or sugar

00619584-071900

residue, or alternatively, taken together form a heterocycle,
as well as the salts thereof and the optical and geometrical isomers thereof.

5 2. Compounds according to Claim 1, characterized in that they are in the form of salts of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.

10 3. Compounds according to Claim 1, characterized in that they are taken, alone or as mixtures, from the group consisting of:

 - 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,

15 - 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propionic acid,

 - 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid,

 - 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,

20 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,

 - 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropionic acid,

25 - 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid,

 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropionic acid,

006720" 48567960

- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropionic acid,
- N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid,
- 5 - 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
- 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
- 10 - 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropionic acid,
- 15 - 2-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 2-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 2-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 20 - 2-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 2-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 25 - 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,

00619584-071500

- 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 5 - 3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid,
- N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
- 10 - N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide,
- 15 - Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate,
- 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,
- 4-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 20 - 4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 4-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 25 - 4-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 4-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,

006720-49567960

- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrolein,

- 3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]prop-2-en-1-ol,

5 - cis-3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,

- cis-3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,

10 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-pyridineacrylic acid,

- 3-(3-Butyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,


- 6-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyridineacrylic acid.

15 4. Compounds according to Claim 1, characterized in that they have at least one, and preferably all, of the following characteristics:

- R_1 represents the radical $-COR_2$
- Ar represents the radicals of formula

20 (a) or (d)

- X represents the radical



- R_2 and R_3 , taken together, form, with the adjacent aromatic ring, a 5- or 6-membered ring optionally substituted with methyl groups and/or

optionally interrupted by an oxygen or sulphur atom.

5. Compounds according to any one of the preceding claims, for use as a medicinal product.

6. Compounds according to Claim 5, for use
5 as a medicinal product intended for the treatment of dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation, in particular for treating common acne, comedones, polymorphonuclear-
10 leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne and secondary acnes such as solar, medication-related or profession-related acne; for treating other types of keratinization disorder, in particular ichthyosis, ichthyosiform states, Darier's
15 disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous or mucous (buccal) lichen; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component and, in
20 particular, all forms of psoriasis, whether it is cutaneous, mucous or ungual psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy; the compounds may also be used
25 for some inflammatory complaints which show no keratinization disorder; for treating all dermal or epidermal hyperproliferations, whether benign or malignant and whether they are of viral origin or

096054 07900
006T20-1856T960

otherwise, such as common warts, flat warts and verruciform epidermodysplasia, it being possible for the oral or florid papillomatoses and the hyperproliferations to be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma; for treating other dermatological disorders such as bullosis and collagen diseases; for treating certain ophthalmological disorders, in particular corneopathies; for repairing or combating ageing of the skin, whether this is light-induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing; for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for preventing or treating cicatrization disorders or for preventing or repairing vibices; for favouring cicatrization, for combating disorders of sebaceous functioning such as the hyperseborrhoea of acne or simple seborrhoea; in the treatment or prevention of cancerous or precancerous states, more particularly promyelocytary leukemia; in the treatment of inflammatory complaints such as arthritis; in the treatment of any general or skin complaint of viral origin; in the prevention or treatment of alopecia; in the treatment of dermatological complaints having an immunological component; in the treatment of complaints

006720-48567960

of the cardiovascular system such as arteriosclerosis or hypertension, as well as insulin-independent diabetes, in the treatment of skin disorders caused by exposure to UV radiation.

5 7. Pharmaceutical composition, characterized in that it comprises, in a pharmaceutically acceptable support, at least one of the compounds as defined in any of Claims 1 to 4.

10 8. Composition according to Claim 7, - characterized in that the concentration of compound(s) according to one of Claims 1 to 4 is between 0.001% and 5% by weight relative to the composition as a whole.

15 9. Cosmetic composition, characterized in that it comprises, in a cosmetically acceptable support, at least one of the compounds as defined in any one of Claims 1 to 4.

20 10. Composition according to Claim 9, - characterized in that the concentration of compound(s) according to one of Claims 1 to 4 is between 0.001% and 3% by weight relative to the composition as a whole.


11. Use of a cosmetic composition as defined in either of Claims 9 and 10, for body or hair hygiene.

006T20" 4856T960

ABSTRACT

BICYCLIC AROMATIC COMPOUNDS

The invention relates to novel bicyclic aromatic compounds which have the general formula (I):



as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

006T20-4886T960




FIG. 1a

FIG. 1b

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.

016800-173

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

BICYCLIC AROMATIC COMPOUNDS

the specification of which

(check one)

☐

is attached hereto;

☒

was filed on 05 March 1997

as

International Application No. PCT/FR97/00391

and was amended on _____;
(if applicable)

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

006T20-4856T960

COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

010315-025

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
France	96/03235	14 March 1996	YES <u>X</u> NO <u> </u>
			YES <u> </u> NO <u> </u>

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis 17,337
 Peter H. Smolka 15,913
 Robert S. Swecker 19,885
 Platon N. Mandros 22,124
 Benton S. Duffett, Jr. 22,030
 Joseph R. Magnone 24,239
 Norman H. Stepno 22,716
 Ronald L. Grudziecki 24,970
 Frederick G. Michaud, Jr. 26,003
 Alan E. Kopecki 25,813
 Regis E. Slutter 26,999
 Samuel C. Miller, III 27,360

Ralph L. Freeland, Jr. 16,110
 Robert G. Mukai 28,531
 George A. Hovanec, Jr. 28,223
 James A. LaBarre 28,632
 E. Joseph Gess 28,510
 R. Danny Huntington 27,903
 Eric H. Weisblatt 30,505
 James W. Peterson 26,057
 Teresa Stanek Rea 30,427
 Robert E. Krebs 25,885
 Robert M. Schulman 31,196

William C. Rowland 30,888
 T. Gene Dillahunt 25,423
 Anthony W. Shaw 30,104
 Patrick C. Keane 32,858
 Bruce J. Boggs, Jr. 32,344
 William H. Benz 25,952
 Peter K. Skiff 31,917
 Richard J. McGrath 29,195
 Matthew L. Schneider 32,814
 Michael G. Savage 32,596
 Gerald F. Swiss 30,113

and:

Address all correspondence to:

Norman H. Stepno
 Burns, Doane, Swecker & Mathis, LLP
 P.O. Box 1404
 Alexandria, Virginia 22313-1404

Address all telephone calls to: Norman H. Stepno at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR		SIGNATURE	DATE
Jean-Michel BERNARDON		Bernardon Jean Michel	12/17/97
RESIDENCE		CITIZENSHIP	
231, Chemin Plan Bergier, 06650 Le Rouret, France		France	
POST OFFICE ADDRESS			
231, Chemin Plan Bergier, 06650 Le Rouret, France			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			